Ben Clark Steps Into Senior Scientist Role at Interius BioTherapeutics
Ben Clark joins Interius BioTherapeutics as Senior Scientist, bringing over a decade of biotech experience to advance next-generation CAR-T therapies using innovative in vivo delivery technology.
August 6, 2024
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Ben Clark steps into the role of Senior Scientist at Interius BioTherapeutics, an early-stage biotechnology company expanding the potential of cell and gene therapy with next-generation delivery technology based on innovations from Dr. Saar Gill’s laboratory at the University of Pennsylvania. At Interius, Ben Clark’s primary role is to help develop the next generation of CARs to be used with Interius’ in vivo targeted LV platform, as well as to develop and optimize the platform for new disease indications. He is enthusiastic about working on Interius’ groundbreaking technology and is dedicated to contributing all he can to ensure its success.
About Ben Clark
Ben Clark holds an MS in Biomedical Sciences and Molecular Biology from Hood College and a Bachelor of Science in Biology from Salisbury College. He is a veteran in the biotech and pharmaceutical industries, with 11 years of experience and a specialized focus on cell and gene therapy, particularly CAR-T cell therapy, over the past 6 years. His career includes significant contributions to the field, including leading key projects at AstraZeneca in Gaithersburg, MD, where he played a critical role in several solid tumor-directed CAR-T pipeline projects. At Precigen Inc. in Germantown, MD, Clark was instrumental in developing non-viral gene delivery platforms for CAR-T gene delivery. Clark’s vision at Interius includes driving the development of transformative therapies and contributing to groundbreaking advancements in cell and gene therapy.
About Interius BioTherapeutics
Interius BioTherapeutics, a leading biotechnology company, is developing novel off-the-shelf gene therapies enabling the generation of autologous chimeric antigen receptor (CAR) cells in vivo using targeted lentiviral vector technology. The company’s lead program is an intravenous in vivo CAR therapy to treat B cell lymphomas, in which proprietary engineering delivers exquisite specificity for target tissues. The company is developing a second program to treat autoimmune diseases. Interius has created a differentiated new therapeutic modality for precision delivery of gene medicines, which could be available to patients without delays, without preconditioning chemotherapy, and in expanded care settings. For more information, visit www.interiusbio.com.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
